<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39457534</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2221</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12102221</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study aimed to evaluate the eicosanoid and pro-resolutive parameters in patients with Post-COVID Syndrome (PCS) during a 12-week supplementation with a marine oil enriched in specialized pro-resolving mediators (SPMs).</AbstractText><AbstractText Label="PATIENT AND METHODS" NlmCategory="METHODS">This study was conducted on 53 adult patients with PCS. The subjects included must have had a positive COVID-19 test (PCR, fast antigen test, or serologic test) and persistent symptoms related to COVID-19 at least 12 weeks before their enrolment in the study. The following parameters were evaluated: polyunsaturated fatty acids EPA, DHA, ARA, and DPA; specialized pro-resolving mediators (SPMs), 17-HDHA, 18-HEPE, 14-HDHA, resolvins, maresins, protectins, and lipoxins. The eicosanoids group included prostaglandins, thromboxanes, and leukotrienes. The development of the clinical symptoms of fatigue and dyspnea were evaluated using the Fatigue Severity Scale (FSS) and the Modified Medical Research Council (mMRC) Dyspnea Scale. Three groups with different intake amounts were evaluated (daily use of 500 mg, 1500 mg, and 3000 mg) and compared to a control group not using the product.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the serum from patients with PCS, an increase in 17-HDHA, 18-HEPE, and 14-HDHA could be observed, and a decrease in the ratio between the pro-inflammatory and pro-resolutive lipid mediators was detected; both differences were significant (<i>p</i> &lt; 0.05). There were no differences found between the three treatment groups. Fatigue and dyspnea showed a trend of improvement after supplementation in all groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A clear enrichment in the serum of the three monohydroxylated SPMs could be observed at a dosage of 500 mg per day. Similarly, a clear improvement in fatigue and dyspnea was observed with this dosage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gracia Aznar</LastName><ForeName>Asun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sociedad Española de Médicos Generales y de Familia (SEMG), 28005 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno Egea</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Solutex GC SL, Avenida de la Transición Espanola 24, 28108 Alcobendas, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gracia Banzo</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Solutex GC SL, Parque Empresarial Utebo, Avda. Miguel Servet nº 81, 50180 Utebo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Rocio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>OTC Chemo, Manuel Pombo Angulo 28-4th Floor, 28050 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizo</LastName><ForeName>Jose Miguel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>OTC Chemo, Manuel Pombo Angulo 28-4th Floor, 28050 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Ledo</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0114-1396</Identifier><AffiliationInfo><Affiliation>Sociedad Española de Médicos Generales y de Familia (SEMG), 28005 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nerin</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-6752-1992</Identifier><AffiliationInfo><Affiliation>Directora de la Cátedra SEMG-Estilos de Vida Unidad de Tabaquismo FMZ Profª Dpto. Medicina, Psiquiatría y Dermatología Facultad de Medicina, Universidad de Zaragoza, 50009 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regidor</LastName><ForeName>Pedro-Antonio</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-9551-2847</Identifier><AffiliationInfo><Affiliation>Exeltis Healthcare, Adalperostr. 84, 85737 Ismaning, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>020</GrantID><Agency>Insud Pharma</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">resolution</Keyword><Keyword MajorTopicYN="N">specialized pro-resolving mediators</Keyword></KeywordList><CoiStatement>Pedro-Antoino Regidor, Rocio Gutierrez and Jose Miguel Rizo are employees of Insud Pharma. SPM: Specialized pro-resolving mediator.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457534</ArticleId><ArticleId IdType="pmc">PMC11505212</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12102221</ArticleId><ArticleId IdType="pii">biomedicines12102221</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu Y.C., Chen C.S., Chan Y.J. Overview of the 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP) J. Chin. Med. Assoc. 2020;11:217–220. doi: 10.1097/JCMA.0000000000000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000270</ArticleId><ArticleId IdType="pmc">PMC7153464</ArticleId><ArticleId IdType="pubmed">32134861</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Roser M., Ritchie H., Ortiz-Ospina E. Coronavirus Disease (COVID-19)-Statistics and Research.  [(accessed on 1 October 2022)].  Available online:  https://ourworldindata.org/coronavirus.</Citation></Reference><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel. Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) JAMA. 2020;323:1824–1836. doi: 10.1001/jama.2020.6019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6019</ArticleId><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Krolewiecki A., Lifschitz A., Moragas M., Travacio M., Valentini R., Alonso D.F., Solari R., Tinelli M.A., Cimino R.O., Álvarez L., et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. eClinicalMedicine. 2021;37:100959. doi: 10.1016/j.eclinm.2021.100959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100959</ArticleId><ArticleId IdType="pmc">PMC8225706</ArticleId><ArticleId IdType="pubmed">34189446</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Elia R.V., Harrison K., Oyston P.C., Lukaszewski R.A., Clark G.C. Targeting the “cytokine storm” for therapeutic benefit. Clin. Vaccine Immunol. 2013;20:319–327. doi: 10.1128/CVI.00636-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00636-12</ArticleId><ArticleId IdType="pmc">PMC3592351</ArticleId><ArticleId IdType="pubmed">23283640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 2020;382:1787–1799. doi: 10.1056/NEJMoa2001282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001282</ArticleId><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S.C., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., Li J., Yao Y., Ge S., Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829–883. doi: 10.1016/j.kint.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.03.005</ArticleId><ArticleId IdType="pmc">PMC7110296</ArticleId><ArticleId IdType="pubmed">32247631</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020;5:811–818. doi: 10.1001/jamacardio.2020.1017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810. doi: 10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Chen R., Liu C., Liang W., Guan W., Tang R., Tang C., Zhang N., Zhong N., Li S. Attention should be paid to venous thromboembolism prophylaxis in managing COVID-19. Lancet Haematol. 2020;7:362–363. doi: 10.1016/S2352-3026(20)30109-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30109-5</ArticleId><ArticleId IdType="pmc">PMC7158946</ArticleId><ArticleId IdType="pubmed">32278361</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Hemost. 2020;18:1094–1099. doi: 10.1111/jth.14817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14817</ArticleId><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Yang L., Liu R., Liu F., Wu K.L., Li J., Liu X.H., Zhu C.L. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin. Chem. Lab. Med. 2020;58:1116–1120. doi: 10.1515/cclm-2020-0188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0188</ArticleId><ArticleId IdType="pubmed">32172226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:1421–1424. doi: 10.1111/jth.14830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14830</ArticleId><ArticleId IdType="pmc">PMC7262324</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan C.N., Dalli J., Colas R.A., Winkler J.W., Chiang N. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim. Biophys Acta. 2015;1851:397–413. doi: 10.1016/j.bbalip.2014.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2014.08.006</ArticleId><ArticleId IdType="pmc">PMC4324013</ArticleId><ArticleId IdType="pubmed">25139562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zheng X., Cheng Y., Zhang Y.L., Wen H.X., Tao Z., Li H., Hao Y., Gao Y., Yang L.-M., et al. Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na, K-ATPase via ALX/cAMP/PI3K pathway in lipopolysaccharide-induced acute lung injury. J. Immunol. 2014;192:3765–3777. doi: 10.4049/jimmunol.1302421.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302421</ArticleId><ArticleId IdType="pubmed">24646745</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan C.N. Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms. FASEB J. 2017;31:1273–1288. doi: 10.1096/fj.201601222R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201601222R</ArticleId><ArticleId IdType="pmc">PMC5349794</ArticleId><ArticleId IdType="pubmed">28087575</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan C.N., Chiang N. Resolution phase lipid mediators of inflammation: Agonists of resolution. Curr. Opin. Pharmacol. 2013;13:632–640. doi: 10.1016/j.coph.2013.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2013.05.012</ArticleId><ArticleId IdType="pmc">PMC3732499</ArticleId><ArticleId IdType="pubmed">23747022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Yan S.F., Hao Y., Jin S.W. Specialized Pro-resolving Mediators Regulate Alveolar Fluid Clearance during Acute Respiratory Distress Syndrome. Chin. Med. J. 2018;131:982–989. doi: 10.4103/0366-6999.229890.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.229890</ArticleId><ArticleId IdType="pmc">PMC5912066</ArticleId><ArticleId IdType="pubmed">29664060</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay M.A., Ware L.B., Zimmerman G.A. Acute respiratory distress syndrome. J. Clin. Investig. 2012;122:2731–2740. doi: 10.1172/JCI60331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI60331</ArticleId><ArticleId IdType="pmc">PMC3408735</ArticleId><ArticleId IdType="pubmed">22850883</ArticleId></ArticleIdList></Reference><Reference><Citation>Cilloniz C., Pantin-Jackwood M.J., Ni C., Goodman A.G., Peng X., Proll S.C., Carter V.S., Rosenzweig E.R., Szretter K.J., Katz J.M., et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse infection model. J. Virol. 2010;84:7613–7624. doi: 10.1128/JVI.00553-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00553-10</ArticleId><ArticleId IdType="pmc">PMC2897611</ArticleId><ArticleId IdType="pubmed">20504916</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz B., Sharma L., Roberts L., Peng X., Bermejo S., Leighton I., Casanovas-Massana A., Minasyan M., Farhadian S., Ko A.I., et al. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. J. Immunol. 2020;206:329–334. doi: 10.4049/jimmunol.2001025.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2001025</ArticleId><ArticleId IdType="pmc">PMC7962598</ArticleId><ArticleId IdType="pubmed">33277388</ArticleId></ArticleIdList></Reference><Reference><Citation>A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. 6 October 2021.  [(accessed on 1 October 2022)].  Available online:  https://iris.who.int/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf?sequence=1.</Citation></Reference><Reference><Citation>Tabas I., Glass C.K. Anti-inflammatory therapy in chronic disease: Challenges and opportunities. Science. 2013;339:166–172. doi: 10.1126/science.1230720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1230720</ArticleId><ArticleId IdType="pmc">PMC3608517</ArticleId><ArticleId IdType="pubmed">23307734</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel Functional Sets of Lipid-derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing. J. Exp. Med. 2000;192:1197–1204. doi: 10.1084/jem.192.8.1197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.192.8.1197</ArticleId><ArticleId IdType="pmc">PMC2195872</ArticleId><ArticleId IdType="pubmed">11034610</ArticleId></ArticleIdList></Reference><Reference><Citation>Serhan C.H., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals. J. Exp. Med. 2002;196:1025–1037. doi: 10.1084/jem.20020760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20020760</ArticleId><ArticleId IdType="pmc">PMC2194036</ArticleId><ArticleId IdType="pubmed">12391014</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannenberg G.L., Chiang N., Ariel A., Arita M., Tjonahen E., Gotlinger K.H., Hong S., Serhan C.H. Molecular circuits of resolution: Formation and actions of resolvins and protectins. J. Immunol. 2005;174:4345–4355. doi: 10.4049/jimmunol.174.7.4345.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.7.4345</ArticleId><ArticleId IdType="pubmed">15778399</ArticleId></ArticleIdList></Reference><Reference><Citation>Spite M., Norling L.V., Summers L., Yang R., Cooper D., Petasis N.A., Flower R.J., Perretti M., Serhan C.H. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461:1287–1291. doi: 10.1038/nature08541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08541</ArticleId><ArticleId IdType="pmc">PMC2779525</ArticleId><ArticleId IdType="pubmed">19865173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang N., Fredman G., Bäckhed F., Oh S.F., Vickery T., Schmidt B.A., Serhan C.N. Infection Regulates Pro-Resolving Mediators that Lower Antibiotic Requirements. Nature. 2012;484:524–528. doi: 10.1038/nature11042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11042</ArticleId><ArticleId IdType="pmc">PMC3340015</ArticleId><ArticleId IdType="pubmed">22538616</ArticleId></ArticleIdList></Reference><Reference><Citation>Elajami T.K., Colas R.A., Dalli J., Chiang N., Serhan C.N., Welty F.K. Specialized pro-resolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016;30:2792–2801. doi: 10.1096/fj.201500155R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201500155R</ArticleId><ArticleId IdType="pmc">PMC4970606</ArticleId><ArticleId IdType="pubmed">27121596</ArticleId></ArticleIdList></Reference><Reference><Citation>Souza P.R., Marques R.M., Gomez E.A., Colas R.A., De Matteis R., Zak A., Patel M., Collier D.J., Dalli J. Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses: A randomized double-blind placebo-controlled study. Circ. Res. 2020;126:75–90. doi: 10.1161/CIRCRESAHA.119.315506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.119.315506</ArticleId><ArticleId IdType="pubmed">31829100</ArticleId></ArticleIdList></Reference><Reference><Citation>Colas R.A., Shinohara M., Dalli J., Chiang N., Serhan C.N. Identification and signature profiles for pro-resolving and inflammatory mediators in human tissue. Am. J. Physiol.-Cell Physiol. 2014;307:C9–C57. doi: 10.1152/ajpcell.00024.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00024.2014</ArticleId><ArticleId IdType="pmc">PMC4080182</ArticleId><ArticleId IdType="pubmed">24696140</ArticleId></ArticleIdList></Reference><Reference><Citation>English J.T., Norris P.C., Hodges R.R., Dartt D.A., Serhan C.N. Identifying and profiling specialized pro-resolving mediators in Human Tears by Lipid Mediator Metabolomics. Prostaglandins Leukot. Essent. Fat. Acids. 2017;117:17–27. doi: 10.1016/j.plefa.2017.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2017.01.004</ArticleId><ArticleId IdType="pmc">PMC5329889</ArticleId><ArticleId IdType="pubmed">28237084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalli J., Colas R.A., Walker M.E., Serhan C.N. Lipid Mediator Metabolomics via LC-MS/MS Profiling and Analysis. In: Giera M., editor. Clinical Metabolomics. Humana; New York, NY, USA: 2018. pp. 59–72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7592-1</ArticleId><ArticleId IdType="pubmed">29363065</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020;130:2620–2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Regidor P.A., De La Rosa X., Santos F.G., Rizo J.M., Gracia Banzo R., Silva R.S. Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids. Eur. Rev. Med. Pharmacol. Sci. 2021;25:6782–6796.</Citation><ArticleIdList><ArticleId IdType="pubmed">34787883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844–847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M., Clark C., Iba T. ISTH interim guidance on recognizing and managing coagulopathy in COVID-19. J. Thromb. Haemost. 2020;18:1023–1026. doi: 10.1111/jth.14810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14810</ArticleId><ArticleId IdType="pmc">PMC9906133</ArticleId><ArticleId IdType="pubmed">32338827</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F.B., Jr., Toh C.H., Hoots W.K., Wada H., Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 2001;86:1327–1330. doi: 10.1055/s-0037-1616068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1616068</ArticleId><ArticleId IdType="pubmed">11816725</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolai L., Leunig A., Brambs S., Kaiser R., Weinberger T., Weigand M., Muenchhoff M., Hellmuth J.C., Ledderose S., Schulz H., et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated with Respiratory Failure and Coagulopathy. Circulation. 2020;142:1176–1189. doi: 10.1161/CIRCULATIONAHA.120.048488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048488</ArticleId><ArticleId IdType="pmc">PMC7497892</ArticleId><ArticleId IdType="pubmed">32755393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherpokova D., Jouvene C.C., Libreros S., DeRoo E.P., Chu L., de la Rosa X., Norris P.C., Wagner D.D., Serhan C.N. Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood. 2019;134:1458–1468. doi: 10.1182/blood.2018886317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2018886317</ArticleId><ArticleId IdType="pmc">PMC6839959</ArticleId><ArticleId IdType="pubmed">31300403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>